Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire

• Main Authors: Jochen G. Mainz (Author), Anton Barucha (Author), Pu Huang (Author), Lilith Bechinger (Author), Franziska Duckstein (Author), Louise Polte (Author), Pauline Sadrieh (Author), Lutz Nährlich (Author), Olaf Eickmeier (Author), Suzanne Van Dullemen (Author), Patience Eschenhagen (Author), Carsten Schwarz (Author), Stefan Lüth (Author), Carlos Zagoya (Author), Ute Graepler-Mainka (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Elexacaftor-tezacaftor-ivacaftor (ETI) is a novel, highly effective CFTR modulator combination proven to enhance lung function and body weight in people with cystic fibrosis (pwCF) carrying a F508del mutation. Recently, we revealed significant reductions in abdominal symptoms (AS) in Ger...